Vial Doses First Patient with Asthma in Phase 1b Study of Vial's IL-13 x TSLP, a Bispecific Antibody Designed for Twice-Yearly Dosing

Phase 1IL-13 x TSLPPositive

AI Analysis

Summary

Vial dosed the first patient with asthma in a Phase 1b study of its IL-13 x TSLP bispecific antibody, designed for twice-yearly dosing to treat Type 2 inflammatory diseases. Prior Phase 1a data in healthy volunteers supported patient progression.

Clinical Trial Data

Phase

Outcome Details

First patient dosed in Phase 1b study

Importance:5/10

Sentiment:

0.60

phase_1basthmabispecific_antibodyil-13tslptype_2_inflammation

Related Companies

$HOST $TRAX

Read the original article

Published by PR Newswire Biotech on October 5, 2026 3:42 PM

Read Original